Proteome-wide mendelian randomization identifies causal plasma proteins in venous thromboembolism development.
Haobo LiZhu ZhangYuting QiuHaoyi WengShuai YuanYunxia ZhangYu ZhangLinfeng XiFeiya XuXiaofan JiRisheng HaoPeiran YangGang ChenXianbo ZuoZhen-Guo ZhaiChen WangPublished in: Journal of human genetics (2023)
Genome-wide association studies (GWAS) have identified numerous risk loci for venous thromboembolism (VTE), but it is challenging to decipher the underlying mechanisms. We employed an integrative analytical pipeline to transform genetic associations to identify novel plasma proteins for VTE. Proteome-wide association studies (PWAS) were determined by functional summary-based imputation leveraging data from a genome-wide association analysis (14,429 VTE patients, 267,037 controls), blood proteomes (1348 cases), followed by Mendelian randomization, Bayesian colocalization, protein-protein interaction, and pathway enrichment analysis. Twenty genetically regulated circulating protein abundances (F2, F11, ABO, PLCG2, LRP4, PLEK, KLKB1, PROC, KNG1, THBS2, SERPINA1, RARRES2, CEL, GP6, SERPINE2, SERPINA10, OBP2B, EFEMP1, F5, and MSR1) were associated with VTE. Of these 13 proteins demonstrated Mendelian randomized correlations. Six proteins (F2, F11, PLEK, SERPINA1, RARRES2, and SERPINE2) had strong support in colocalization analysis. Utilizing multidimensional data, this study suggests PLEK, SERPINA1, and SERPINE2 as compelling proteins that may provide key hints for future research and possible diagnostic and therapeutic targets for VTE.
Keyphrases
- venous thromboembolism
- genome wide association
- direct oral anticoagulants
- protein protein
- genome wide
- end stage renal disease
- small molecule
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- prognostic factors
- gene expression
- transcription factor
- artificial intelligence
- clinical trial
- peritoneal dialysis
- patient reported outcomes
- dna methylation
- copy number
- data analysis
- study protocol